

## Starship Child Health Individual Zoledronic acid Treatment plan

Date:	Patient sticker:	Patient sticker:		
Paediatric Endocrinolo	gist:			
Reason for treatment:				
Diagnoses:				
Recent weight:	kg or use lean mass for dosing (DMD e	tc.)		
Zoledronic acid (Aclast		or N/A		
Length of treatment estimated to be:		or at	Date:	
Next review by SMO F	Paed Endo:	or	Date:	

### **General overview of Infusions**

#### **Further infusions**

• If tolerated 1<sup>st</sup> infusion well, with minimal side effects AND no hypocalcaemia: arrange a 2nd at 4-6 weeks (Dose will be 0.0375 mg/kg: the balance of a 0.05 mg/kg/dose). Aim to check calcium 24 - 48 hours post infusion, and if stable no need to repeat checks after future infusions unless concerned.

#### OR

- If not tolerated well (lots of pain &/or hypocalcaemia): arrange 2<sup>nd</sup> infusion in 4-6 weeks as an inpatient with a repeat dose of 0.0125 mg/kg. 3<sup>rd</sup> dose will be pending how much reaction there is etc.; aiming to give a total of 0.05 mg/kg in the first 6 months: so for this case a 3rd dose will be 0.025 mg/kg.
- \*If on full milk feeds (G-Tube etc.) and vitamin D is normal, not likely to need additional calcium or calcitriol



# Starship Child Health Individual Zoledronic acid Treatment plan

Paediatric Endocrinology zoledronic acid (Aclasta®) Repeat infusions					
Dat	te:	Patient sticker:			
Sta	Standard infusions are six monthly and are at 0.05 mg/kg for 6 monthly infusions  Checklist for zoledronic acid repeat infusions  Fracture history in last 6 months (any fractures and what type? Nil or describe below				
Ch					
Fra					
Pre	e-first infusion				
	<ul> <li>Full blood count</li> </ul>	Normal or			
	<ul> <li>Urea and electrolytes</li> </ul>	Normal or			
	<ul> <li>Liver function tests</li> </ul>	Normal or			
	• 25-hydroxy vitamin D	Normal or			
	<ul> <li>Parathyroid hormone</li> </ul>	Normal or			
	<ul> <li>Calcium</li> </ul>	Normal or			
	<ul> <li>Magnesium</li> </ul>	Normal or			
	<ul> <li>Phosphate</li> </ul>	Normal or			
	·	locrine Bisphosphonate Starship Clinical Guideline) Height:			
Cha	art medication: Zoledronic a				
Pos	<ul><li>Ensure has pain relief,</li><li>Ensure they have regul</li><li>The week of calcium or</li></ul>	calcium checked at 48 hours NSAID and ondansetron on discharge lar vitamin D: normally monthly cholecalciferol tablets. r calcitriol/1-alpha post-infusion is normally only required after the 1 <sup>st</sup> and 2 <sup>nd</sup>			
	infusions. It is not normally required after the 3 <sup>rd</sup> infusion onwards, but encourage a high calcium diet.				
<ul> <li>Plan next infusion (first is on ward, if tolerated the rest are in DSU)</li> <li>DSU or Ward 26A (circle one)</li> <li>Email: DSU scheduler for next infusion in 6 weeks: starshipoutpatients@adhb.govt.nz</li> <li>Expected Date:</li> </ul>					
AN	D				
	<ul> <li>Email: Sherylt@adhb.govt.nz (to update Excel list on L drive) (Endocrine CNS)</li> <li>Dictate discharge letter to GP – cc to family, Consultant, (local paediatrician if relevant) and Endocrine Nurse (Sheryl Tregurtha)</li> </ul>				
	Checklist completed by:	Date:			

Signature:

For Consultant: